STOCK TITAN

[Form 4] STERIS plc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Karen L. Burton, VP & CAO and a company officer of STERIS plc (STE), reported a sale and an outstanding option in a Form 4 filing. On 08/11/2025 she sold 7,900 ordinary shares at a weighted average price of $241.73 per share (sales ranged from $241.33 to $242.32), reducing her direct beneficial ownership to 5,994 ordinary shares.

She continues to hold a fully vested employee stock option to purchase 7,900 ordinary shares at a strike price of $114.22 that originated from the company’s March 2019 redomiciliation exchange. Of the remaining shares, 3,216 are restricted and vest in scheduled tranches between October 1, 2025 and June 5, 2028.

Karen L. Burton, VP e CAO e dirigente della STERIS plc (STE), ha segnalato una vendita e un'opzione in essere in una dichiarazione Form 4. Il 08/11/2025 ha venduto 7,900 azioni ordinarie a un prezzo medio ponderato di $241.73 per azione (operazioni comprese tra $241.33 e $242.32), riducendo la sua proprietà diretta beneficiaria a 5,994 azioni ordinarie.

Continua a detenere un'opzione azionaria per dipendenti completamente maturata per acquistare 7,900 azioni ordinarie a un prezzo di esercizio di $114.22, originata dallo scambio legato alla ridomiciliazione della società avvenuta nel marzo 2019. Delle azioni rimanenti, 3,216 sono vincolate e si liberano in tranche programmate tra il 1° ottobre 2025 e il 5 giugno 2028.

Karen L. Burton, VP y CAO y ejecutiva de STERIS plc (STE), informó una venta y una opción pendiente en una declaración Form 4. El 08/11/2025 vendió 7,900 acciones ordinarias a un precio medio ponderado de $241.73 por acción (operaciones entre $241.33 y $242.32), reduciendo su propiedad beneficiaria directa a 5,994 acciones ordinarias.

Sigue manteniendo una opción sobre acciones de empleados totalmente devengada para comprar 7,900 acciones ordinarias con un precio de ejercicio de $114.22, originada en el intercambio por la redomiciliación de la compañía en marzo de 2019. De las acciones restantes, 3,216 están restringidas y se adquieren por tramos programados entre el 1 de octubre de 2025 y el 5 de junio de 2028.

Karen L. Burton, VP 및 CAO이자 STERIS plc (STE)의 임원은 Form 4 신고서에서 매도와 미결 옵션을 보고했습니다. 08/11/2025에 그녀는 가중평균 가격 주당 $241.737,900 보통주를 매도(거래 범위 $241.33~$242.32)하여 직접적 수익 소유 지분을 5,994 보통주로 줄였습니다.

그녀는 계속해서 행사 가격이 $114.22인 전액 베스팅된 직원 주식매수선택권 7,900주를 보유하고 있으며, 이는 2019년 3월 회사의 redomiciliation 교환에서 유래했습니다. 나머지 주식 중 3,216주는 제한주로 2025년 10월 1일부터 2028년 6월 5일까지 예정된 일정에 따라 베스팅됩니다.

Karen L. Burton, VP & CAO et dirigeante de STERIS plc (STE), a déclaré une vente et une option en cours dans un dépôt Form 4. Le 08/11/2025, elle a vendu 7,900 actions ordinaires à un prix moyen pondéré de $241.73 par action (transactions entre $241.33 et $242.32), réduisant sa détention bénéficiaire directe à 5,994 actions ordinaires.

Elle conserve une option d'achat d'actions attribuée aux employés, entièrement acquise, portant sur 7,900 actions ordinaires au prix d'exercice de $114.22, issue de l'échange lié à la redomiciliation de la société en mars 2019. Parmi les actions restantes, 3,216 sont restreintes et se libèrent par tranches prévues entre le 1er octobre 2025 et le 5 juin 2028.

Karen L. Burton, VP & CAO und leitende Beauftragte von STERIS plc (STE), meldete in einer Form‑4‑Einreichung einen Verkauf und eine ausstehende Option. Am 08/11/2025 verkaufte sie 7,900 Stammaktien zu einem gewichteten Durchschnittspreis von $241.73 pro Aktie (Handelsspanne $241.33 bis $242.32) und verringerte damit ihr direktes wirtschaftliches Eigentum auf 5,994 Stammaktien.

Sie hält weiterhin eine vollständig unverfallte Mitarbeiteraktienoption zum Kauf von 7,900 Stammaktien zum Ausübungspreis von $114.22, die aus dem Redomiciliation‑Tausch des Unternehmens im März 2019 stammt. Von den verbleibenden Aktien sind 3,216 eingeschränkt und werden in geplanten Tranchen zwischen dem 1. Oktober 2025 und dem 5. Juni 2028 freigegeben.

Positive
  • Holds a fully vested employee stock option to purchase 7,900 shares at a strike of $114.22, providing potential long-term alignment with shareholders.
  • Sale disclosed with weighted average price range ($241.33–$242.32), increasing transparency about the executed transactions.
Negative
  • Sold 7,900 ordinary shares, reducing direct beneficial ownership to 5,994 shares — a material disposition disclosed in the Form 4.
  • Only 5,994 shares remain in direct beneficial ownership, of which 3,216 are restricted and subject to a staggered vesting schedule.

Insights

TL;DR: Officer sold 7,900 shares at ~$241.7, retained 5,994 shares and holds a fully vested option for 7,900 shares at $114.22.

The reported sale of 7,900 shares at a weighted average of $241.73 is a significant, discrete insider disposition and reduces direct ownership to 5,994 shares. The filing also discloses a fully vested employee stock option covering 7,900 shares with a $114.22 exercise price that dates to the March 2019 redomiciliation exchange. The combination of a large sale and a sizable vested option means the officer retains meaningful economic exposure and upside potential while realizing proceeds from existing equity. For investors, this is material disclosure of insider activity but does not by itself indicate operational changes at the company.

TL;DR: Form 4 shows routine insider reporting: a sizable sale, retained restricted shares, and a legacy vested option from redomiciliation.

The report is complete in its disclosures: sale price range ($241.33–$242.32), post-transaction beneficial ownership (5,994 shares), and detailed vesting schedule for 3,216 restricted shares. The filing also documents the treatment of a legacy option grant tied to the company’s March 2019 redomiciliation. From a governance standpoint, the disclosure meets Rule 16 reporting requirements and provides transparent vesting and option information for stakeholders assessing insider alignment.

Karen L. Burton, VP e CAO e dirigente della STERIS plc (STE), ha segnalato una vendita e un'opzione in essere in una dichiarazione Form 4. Il 08/11/2025 ha venduto 7,900 azioni ordinarie a un prezzo medio ponderato di $241.73 per azione (operazioni comprese tra $241.33 e $242.32), riducendo la sua proprietà diretta beneficiaria a 5,994 azioni ordinarie.

Continua a detenere un'opzione azionaria per dipendenti completamente maturata per acquistare 7,900 azioni ordinarie a un prezzo di esercizio di $114.22, originata dallo scambio legato alla ridomiciliazione della società avvenuta nel marzo 2019. Delle azioni rimanenti, 3,216 sono vincolate e si liberano in tranche programmate tra il 1° ottobre 2025 e il 5 giugno 2028.

Karen L. Burton, VP y CAO y ejecutiva de STERIS plc (STE), informó una venta y una opción pendiente en una declaración Form 4. El 08/11/2025 vendió 7,900 acciones ordinarias a un precio medio ponderado de $241.73 por acción (operaciones entre $241.33 y $242.32), reduciendo su propiedad beneficiaria directa a 5,994 acciones ordinarias.

Sigue manteniendo una opción sobre acciones de empleados totalmente devengada para comprar 7,900 acciones ordinarias con un precio de ejercicio de $114.22, originada en el intercambio por la redomiciliación de la compañía en marzo de 2019. De las acciones restantes, 3,216 están restringidas y se adquieren por tramos programados entre el 1 de octubre de 2025 y el 5 de junio de 2028.

Karen L. Burton, VP 및 CAO이자 STERIS plc (STE)의 임원은 Form 4 신고서에서 매도와 미결 옵션을 보고했습니다. 08/11/2025에 그녀는 가중평균 가격 주당 $241.737,900 보통주를 매도(거래 범위 $241.33~$242.32)하여 직접적 수익 소유 지분을 5,994 보통주로 줄였습니다.

그녀는 계속해서 행사 가격이 $114.22인 전액 베스팅된 직원 주식매수선택권 7,900주를 보유하고 있으며, 이는 2019년 3월 회사의 redomiciliation 교환에서 유래했습니다. 나머지 주식 중 3,216주는 제한주로 2025년 10월 1일부터 2028년 6월 5일까지 예정된 일정에 따라 베스팅됩니다.

Karen L. Burton, VP & CAO et dirigeante de STERIS plc (STE), a déclaré une vente et une option en cours dans un dépôt Form 4. Le 08/11/2025, elle a vendu 7,900 actions ordinaires à un prix moyen pondéré de $241.73 par action (transactions entre $241.33 et $242.32), réduisant sa détention bénéficiaire directe à 5,994 actions ordinaires.

Elle conserve une option d'achat d'actions attribuée aux employés, entièrement acquise, portant sur 7,900 actions ordinaires au prix d'exercice de $114.22, issue de l'échange lié à la redomiciliation de la société en mars 2019. Parmi les actions restantes, 3,216 sont restreintes et se libèrent par tranches prévues entre le 1er octobre 2025 et le 5 juin 2028.

Karen L. Burton, VP & CAO und leitende Beauftragte von STERIS plc (STE), meldete in einer Form‑4‑Einreichung einen Verkauf und eine ausstehende Option. Am 08/11/2025 verkaufte sie 7,900 Stammaktien zu einem gewichteten Durchschnittspreis von $241.73 pro Aktie (Handelsspanne $241.33 bis $242.32) und verringerte damit ihr direktes wirtschaftliches Eigentum auf 5,994 Stammaktien.

Sie hält weiterhin eine vollständig unverfallte Mitarbeiteraktienoption zum Kauf von 7,900 Stammaktien zum Ausübungspreis von $114.22, die aus dem Redomiciliation‑Tausch des Unternehmens im März 2019 stammt. Von den verbleibenden Aktien sind 3,216 eingeschränkt und werden in geplanten Tranchen zwischen dem 1. Oktober 2025 und dem 5. Juni 2028 freigegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burton Karen L

(Last) (First) (Middle)
70 SIR JOHN ROGERSON'S QUAY

(Street)
DUBLIN 2 L2 D02 R296

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP & CAO
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 08/11/2025 M 7,900 A $114.22 13,894 D
Ordinary Shares 08/11/2025 S 7,900 D $241.73(1) 5,994(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $114.22 08/11/2025 M 7,900 (3) 05/31/2028 Ordinary Shares 7,900 $0 0 D
Explanation of Responses:
1. Price reflects a weighted average sale price for multiple transactions ranging from $241.33 to $242.32 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
2. As of August 12, 2025, 3,216 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 86 on October 1, 2025; 340 on June 1, 2026; 651 on June 3, 2026; 225 on June 2, 2026; 306 on June 4, 2026; 651 on June 3, 2027; 306 on June 4, 2027 and 651 on June 5, 2028.
3. This option to purchase 7,900 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 7,900 ordinary shares for $114.22 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.
Remarks:
/s/ John P. Ubbing, Authorized Representative under Power of Attorney 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for STERIS (STE) filed by Karen L. Burton disclose?

The Form 4 discloses a sale of 7,900 ordinary shares on 08/11/2025 at a weighted average price of $241.73, post-transaction ownership of 5,994 shares, and a fully vested option to purchase 7,900 shares at $114.22.

How many of Karen Burton's remaining STERIS shares are restricted and when do they vest?

3,216 shares are restricted, with vesting tranches of 86 on Oct 1, 2025; 340 on Jun 1, 2026; 651 on Jun 3, 2026; 225 on Jun 2, 2026; 306 on Jun 4, 2026; 651 on Jun 3, 2027; 306 on Jun 4, 2027; and 651 on Jun 5, 2028.

What is the strike price and origin of the option reported by Karen Burton on the Form 4?

The option covers 7,900 ordinary shares with a strike price of $114.22, is fully vested, and was received in connection with STERIS plc’s redomiciliation in March 2019 in exchange for the original Old STERIS option.

What sale price details are provided in the Form 4 for the 7,900 shares sold?

The filing reports a weighted average sale price of $241.73 per share and states sales occurred at prices ranging from $241.33 to $242.32.

Did the Form 4 indicate a change in option terms or exercise on 08/11/2025?

The Form 4 shows a derivative security entry relating to the existing option (strike $114.22) and notes the option is fully vested from the prior redomiciliation exchange; it does not explicitly state an exercise occurred.
Steris Plc

NYSE:STE

STE Rankings

STE Latest News

STE Latest SEC Filings

STE Stock Data

24.01B
98.18M
0.3%
95.58%
0.86%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
DUBLIN